Evidence map›Paper›PMID 40823937›Full record

ArticleFuture science OA2025

Elevated serum interleukin-41 levels as a potential biomarker in ankylosing spondylitis.

Wubing Lu, Zhi Li, Shanjun Shi, Sicen Meng, Jieru Pang, Yan Li, Mingcai Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wubing LuDepartment of Immunology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Zhi LiDepartment of Immunology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Shanjun ShiDepartment of Immunology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Sicen MengDepartment of Immunology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Jieru PangDepartment of Immunology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Yan LiDepartment of Immunology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Mingcai LiDepartment of Immunology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterleukin (IL)-41 is a novel cytokine, also known as Metrnl, and its role in ankylosing spondylitis (AS) remains unknown. The aim of this study is to measure the serum IL-41 levels in AS patients and their correlation with other clinical indicators.

methodsThis study recruited 106 participants, including 32 active AS patients, 32 inactive AS patients, and 42 healthy controls (HC). Basic information and clinical indicators of participants were obtained through physical examination and blood sample testing. Enzyme-linked immunosorbent assay was used to detect IL-41 levels.

resultsPatients with active and inactive AS had significantly higher serum IL-41 levels than HC. Moreover, correlation analysis showed that IL-41 in active AS was positively correlated with lymphocyte percentage; IL-41 in inactivated AS is negatively correlated with alkaline phosphatase and creatinine. IL-41 as an independent protective factor for AS had good value for the diagnosis of AS.

conclusionThis study indicates that serum IL-41 levels are elevated in both active and inactive AS patients, suggesting that IL-41 may be a novel biomarker for AS.

Indexed as

alkaline phosphataseAnkylosing spondylitiscreatininediagnostic markerinterleukin-41lymphocyte percentageMetrnl

Identifiers

PMID40823937
PMCPMC12363499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.